On Tuesday, a US appeals court announced that it will expedite the review of Illumina’s challenge against a federal agency’s order for the company to sell Grail, a cancer diagnostic test maker.
The 5th U.S. Circuit Court of Appeals in New Orleans made a decision despite the Federal Trade Commission’s objection. The commission stated that Illumina had not provided sufficient reasoning for the court to expedite its review of the antitrust conflict.
San Diego-based company Illumina, which specializes in gene sequencing, is currently appealing an FTC order issued on April 3rd. The order asserted that Illumina’s acquisition of Grail for $7.1 billion would result in reduced competition within the cancer-testing market. Illumina has denied these allegations.
Related: When Bad Antitrust Costs Lives: The Illumina/GRAIL Tragedy
The FTC expressed concern about the accelerated pace of the litigation and argued that an expedited schedule would be detrimental to its case due to the number and complexity of the issues Illumina plans to bring up, as per their statement to the 5th Circuit.
Attorneys for Illumina stated in a court filing that expedited review could potentially provide earlier access to a cancer screening test and remove obstacles in the fight against cancer.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI